Related Experiment Video
Updated: Oct 29, 2025
Biochemical Measurement of Neonatal Hypoxia
Published on: August 24, 2011
Blood Plasma Metabolic Profile of Newborns with Hypoxic-Ischaemic Encephalopathy by GC-MS
Yanjuan Jia1,2, Xiaoni Jia3, Hui Xu1,2
1NHC Key Laboratory of Diagnosis and Therapy of Gastrointestinal Tumor, Gansu Provincial Hospital, Lanzhou, China 730000.
Insights
Early diagnosis of hypoxic-ischaemic encephalopathy (HIE) in newborns is vital. This study identified plasma metabolic signatures and potential biomarkers, including alpha-ketoglutaric acid, for early HIE detection and severity assessment.
Area of Science:
- Neonatal Medicine
- Metabolomics
- Biomarker Discovery
Background:
- Hypoxic-ischaemic encephalopathy (HIE) poses significant risks for neurodevelopmental disabilities, morbidity, and mortality in newborns.
- Early diagnosis is critical for timely intervention and improved outcomes.
- Investigating peripheral blood metabolic signatures offers a promising avenue for HIE detection.
Purpose of the Study:
- To identify plasma metabolic signatures in newborns with HIE.
- To explore potential diagnostic biomarkers for early HIE detection.
- To evaluate the diagnostic value of identified metabolites.
Main Methods:
- Recruited 24 newborns with HIE and 24 healthy controls.
- Analyzed plasma metabolites using gas chromatography-mass spectrometry (GC-MS).
- Employed multivariate statistics and bioinformatics for differential metabolite and pathway analysis.
Main Results:
- Multivariate models effectively distinguished HIE cases from controls.
- Identified 52 annotated metabolites and enriched 331 significantly changed pathways.
- Discovered 14 candidate metabolites with diagnostic potential for HIE, including alpha-ketoglutaric acid for severity assessment.
Conclusions:
- Plasma metabolic profiling reflects systemic metabolic disturbances in HIE.
- Several candidate metabolites show promise as early diagnostic biomarkers for HIE.
- Further validation in large clinical cohorts and standardization of methods are needed for clinical application.
Background:
Early diagnosis of hypoxic-ischaemic encephalopathy (HIE) is crucial in preventing neurodevelopmental disabilities and reducing morbidity and mortality. The study was to investigate the plasma metabolic signatures in the peripheral blood of HIE newborns and explore the potential diagnostic biomarkers.
Method:
In the present study, 24 newborns with HIE and 24 healthy controls were recruited. The plasma metabolites were measured by gas chromatography-mass spectrometry (GC-MS), and the raw data was standardized by the EigenMS method. Significantly differential metabolites were identified by multivariate statistics. Pathway enrichment was performed by bioinformatics analysis. Meanwhile, the diagnostic value of candidate biomarkers was evaluated.
Result:
The multivariate statistical models showed a robust capacity to distinguish the HIE cases from the controls. 52 metabolites were completely annotated. 331 significantly changed pathways were enriched based on seven databases, including 33 overlapped pathways. Most of them were related to amino acid metabolism, energy metabolism, neurotransmitter biosynthesis, pyrimidine metabolism, the regulation of HIF by oxygen, and GPCR downstream signaling. 14 candidate metabolites showed great diagnostic potential on HIE. Among them, alpha-ketoglutaric acid has the potential to assess the severity of HIE in particular.
Conclusion:
The blood plasma metabolic profile could comprehensively reflect the metabolic disorders of the whole body under hypoxia-ischaemic injury. Several candidate metabolites may serve as promising biomarkers for the early diagnosis of HIE. Further validation based on large clinical samples and the establishment of guidelines for the clinical application of mass spectrometry data standardization methods are imperative in the future.
